This module uses fundamental data of Instadose Pharma to approximate its Piotroski F score. Instadose Pharma F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Instadose Pharma Corp. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Instadose Pharma financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Instadose Pharma Altman Z Score, Instadose Pharma Correlation, Instadose Pharma Valuation, as well as analyze Instadose Pharma Alpha and Beta and Instadose Pharma Hype Analysis.
Instadose
Piotroski F Score
Working Capital
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Invested Capital
Average Payables
Pb Ratio
Roic
Net Income Per Share
Pocfratio
Pfcf Ratio
Net Current Asset Value
Income Quality
Roe
Tangible Asset Value
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Earnings Yield
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Cash Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Non Cash Items
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
Change To Netincome
Change To Liabilities
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Net Debt
Retained Earnings
Accounts Payable
Other Stockholder Equity
Total Liab
Net Invested Capital
Short Long Term Debt
Net Working Capital
Other Current Liab
Capital Stock
Selling General Administrative
Operating Income
Net Income From Continuing Ops
Ebit
Total Operating Expenses
Income Before Tax
Net Income Applicable To Common Shares
Probability Of Bankruptcy
At present, Instadose Pharma's Debt Ratio is projected to increase significantly based on the last few years of reporting. The current year's Cash Flow To Debt Ratio is expected to grow to 0, whereas Short and Long Term Debt is forecasted to decline to about 36.8 K. At present, Instadose Pharma's Average Payables is projected to increase significantly based on the last few years of reporting. The current year's ROIC is expected to grow to 2.73, whereas Book Value Per Share is projected to grow to (0).
At this time, it appears that Instadose Pharma's Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to Instadose Pharma is to make sure Instadose is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Instadose Pharma's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Instadose Pharma's financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Instadose Pharma's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Instadose Pharma in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Book Value Per Share
(0.002969)
At present, Instadose Pharma's Book Value Per Share is projected to slightly decrease based on the last few years of reporting.
About Instadose Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Instadose Pharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Instadose Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Instadose Pharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Instadose Pharma Corp is a strong investment it is important to analyze Instadose Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Instadose Pharma's future performance. For an informed investment choice regarding Instadose Stock, refer to the following important reports:
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Instadose Pharma. If investors know Instadose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Instadose Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.01)
Return On Assets
(694.06)
The market value of Instadose Pharma Corp is measured differently than its book value, which is the value of Instadose that is recorded on the company's balance sheet. Investors also form their own opinion of Instadose Pharma's value that differs from its market value or its book value, called intrinsic value, which is Instadose Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Instadose Pharma's market value can be influenced by many factors that don't directly affect Instadose Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Instadose Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Instadose Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Instadose Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.